Engineered red blood cells coexpressing 4-1BBL and IL-15TP RTX-240

{
  "id": "MLC-T-ONC-013347",
  "term": "Engineered red blood cells coexpressing 4-1BBL and IL-15TP RTX-240",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of allogeneic, off-the-shelf (OTS) red blood cells (RBCs) engineered to express both the co-stimulatory molecule tumor necrosis factor ligand superfamily (TNFSF) member 9 (TNFSF9; 4-1BBL) and a fusion protein composed of the trans-presented cytokine interleukin (IL)-15/IL-15-receptor alpha (IL-15Ra) (IL-15TP) with potential modulating and antineoplastic activities. CD34+ hematopoietic precursor cells (HPC) are collected by apheresis from a healthy O negative donor, purified, and engineered with a lentiviral vector to express 4-1BBL and IL-15TP. The cells are then further expanded and differentiated until the nucleus is ejected, resulting in a mature reticulocyte. Upon administration of the engineered red blood cells co-expressing 4-1BBL and IL-15TP RTX-240, the RBCs express both 4-1BBL and IL-15TP on their cell surfaces. 4-1BBL and IL-15TP bind to and subsequently induce the proliferation and activation of natural killer (NK) cells and T cells. This enhances the secretion of cytokine interferon-gamma (IFN-g) and results in the induction of an anti-tumor immune response.",
  "synonyms": [
    "allogeneic red cells expressing 4-1BBL and IL-15TP",
    "engineered RBCs coexpressing 4-1BBL and IL-15TP RTX-240"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/engineered-red-blood-cells-coexpressing-4-1bbl-and-il-15tp-rtx-240/"
}